Skip to main content
Premium Trial:

Request an Annual Quote

Amersham to Distribute InforMax Software in Latin America

SAN DIEGO, Oct. 26 – Amersham Biosciences has agreed to distribute InforMax’s desktop software in Latin America, the companies announced Friday.

In the exclusive distribution agreement, Piscataway, NJ-based Amersham will distribute InforMax’s Vector NTI Suite molecular biology software in Brazil, Argentina, Bolivia, Guyana, Colombia, Peru, Surinam, French Guiana, Chile, Nicaragua, Venezuela, Ecuador, Uruguay, Paraguay, Mexico, Panama, El Salvador, Honduras, Guatemala, Costa Rica, and all Caribbean countries except Cuba. 

Financial details of the agreement were not disclosed.

“Amersham Biosciences' leadership position in Latin America will be instrumental in expanding our customer base in those countries,” Alex Titomirov, CEO of Bethesda, Md.-based InforMax, said in a statement.

Last week, InforMax announced major changes in its leadership , including Titomirov, who is also chairman of InforMax’s board, stepping down from his CEO position upon the hiring of a replacement.

Amersham Biosciences, which last week was renamed from its former name Amersham Pharmacia Biotech , owns an equity stake in InforMax as part of a September 2000 collaboration deal integrating Amersham’s high throughput platforms with InforMax’s GenoMax software.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.